Group 1 - The core point of the article is that the HPV vaccine has been officially included in the national immunization program, allowing eligible girls to receive free vaccination services [3][4]. Group 2 - The target population for the HPV vaccine includes girls who are 13 years old and above, specifically those born after November 10, 2011 [4]. - Eligible individuals can receive two doses of the bivalent HPV vaccine for free, with the second dose administered six months after the first, and the interval should not exceed one year [5]. - The vaccination can be administered simultaneously with other vaccines at different injection sites [5]. Group 3 - Important considerations for vaccination include the requirement for a guardian to accompany the child, bringing identification documents, and monitoring for 30 minutes post-vaccination for any adverse reactions [5].

Core Points - The National Health Commission and six other departments announced the inclusion of the HPV vaccine in the national immunization program starting November 10, 2025, providing free vaccinations for girls born after November 10, 2011, who are at least 13 weeks old [1] - Cervical cancer is a common malignant tumor among women, posing significant health risks, and the government has initiated a plan to accelerate the elimination of cervical cancer from 2023 to 2030 [1] - Currently, 18 provinces have implemented policies to provide free HPV vaccinations or subsidies for eligible girls, laying a practical foundation for the national inclusion of the HPV vaccine [1]

Group 1 - The Chinese government has decided to include the HPV vaccine in the national immunization program starting from November 10, 2025, targeting girls born after November 10, 2011, who are 13 years old, providing them with two doses of the bivalent HPV vaccine for free [1][2] - The decision is based on the rising incidence and mortality rates of cervical cancer in China, particularly among younger populations, highlighting the importance of HPV vaccination in preventing high-risk HPV infections and reducing the occurrence of cervical cancer [1][2] - The World Health Organization recommends vaccinating girls aged 9 to 14 years before they become sexually active, while China has set the target group for free vaccination at 13 years old, considering the optimal balance of protection effectiveness, cost-effectiveness, and operational feasibility [1][2] Group 2 - The notification emphasizes the need for monitoring the production and supply of HPV vaccines, with various departments responsible for ensuring stable production and addressing challenges faced by manufacturers [2] - China has a total annual production capacity of 55 million doses of the bivalent HPV vaccine from two domestic manufacturers, which is sufficient to meet market demand, and these vaccines have received pre-certification from the World Health Organization [2] - The first domestically produced nine-valent HPV vaccine was approved for market use in mid-2023, marking it as the second nine-valent HPV vaccine globally and breaking the long-standing market monopoly held by foreign products [2]

Group 1 - The inclusion of the HPV vaccine in the national immunization program is a significant step towards reducing the burden of cervical cancer in China and promoting public health [4][5] - The target population for the free vaccination program is girls aged 13 years and older, who will receive two doses of the bivalent HPV vaccine, with a six-month interval between doses [4] - In 2022, approximately 151,000 new cases of cervical cancer were reported in China, with around 56,000 deaths, highlighting the urgency of preventive measures [4] Group 2 - The domestic production capacity for the bivalent HPV vaccine is 55 million doses annually, sufficient to meet market demand, and both manufacturers have received pre-certification from the World Health Organization [5] - The initiative to include the HPV vaccine in the national immunization program represents a new phase in China's immunization efforts, aiming to enhance health equity and accessibility [5] - The collaboration among various departments is essential to ensure the smooth implementation of the vaccination policy, which aims to protect more girls from cervical cancer [5]

Core Points - The Chinese government has committed to providing free HPV vaccinations for girls aged 13 and above, starting from November 10, 2025, as part of the national immunization program [1][2] - This initiative aims to reduce the financial burden of cervical cancer on families and promote public health [1] - Cervical cancer is a significant health threat to women, with approximately 151,000 new cases and 56,000 deaths reported in China in 2022 [1] Group 1 - The policy will allow eligible girls to receive two doses of the bivalent HPV vaccine for free, with a six-month interval between doses [2] - The initiative is designed to improve vaccination rates and ensure equitable access across different regions and income groups [2] - The decision to target 13-year-old girls is based on considerations of protection effectiveness, cost-effectiveness, and operational feasibility [2] Group 2 - The domestic production capacity for the bivalent HPV vaccine is 55 million doses annually, sufficient to meet market demand [3] - The inclusion of the HPV vaccine in the national immunization program marks a new phase in China's immunization efforts [3] - The initiative reflects China's commitment to women's health and aims to contribute to global health equity [3]

Core Points - The Chinese government has included the human papillomavirus (HPV) vaccine in the national immunization program [3] - Girls born after November 10, 2011, who are 13 years old or older, can receive two doses of the bivalent HPV vaccine for free [2][3] - The bivalent HPV vaccine targets the 16 and 18 genotypes of the virus and is administered with a six-month interval between doses [3] Summary by Category - **Government Policy** - The inclusion of the HPV vaccine in the national immunization program is approved by the State Council [3] - **Target Population** - The program specifically targets girls who were born after November 10, 2011, and are at least 13 years old [2][3] - **Vaccine Details** - The vaccine provided is a bivalent type, focusing on genotypes 16 and 18, with a recommended administration schedule of two doses spaced six months apart [3]

Group 1 - The core viewpoint is that the HPV vaccine has been included in the national immunization program in China, allowing for free vaccination for eligible girls [4] - The vaccine is specifically targeted at girls born after November 10, 2011, who are 13 years old or older, and they can receive two doses of the bivalent HPV vaccine for free [2][4] - The vaccination will cover the HPV types 16 and 18, which are known to be associated with cervical cancer [4] Group 2 - The vaccination will be administered in two doses with a six-month interval between them [4] - This initiative is part of the government's efforts to enhance public health and prevent HPV-related diseases [4]

Core Viewpoint - The inclusion of the HPV vaccine in the national immunization program represents a significant commitment to women's health in China, aiming to reduce the burden of cervical cancer and promote public health [4][7]. Group 1: HPV Vaccine Implementation - The HPV vaccine will be available for free to girls who turn 13 years old after November 10, 2011, starting from November 10, 2025, with a total of two doses administered six months apart [4]. - In 2022, there were approximately 151,000 new cases of cervical cancer and about 56,000 deaths in China, highlighting the urgent need for preventive measures [4]. - The initiative aims to improve vaccination rates and reduce disparities in access among different regions and income groups, ensuring equitable health services for the target population [4][6]. Group 2: Immunization Effectiveness - Vaccinating girls at the age of 13 is expected to yield higher antibody levels and more durable protection against HPV [5]. - The decision to target 13-year-old girls for free vaccination is based on considerations of effectiveness, cost-benefit, and operational feasibility [4]. Group 3: Vaccine Production and Capacity - The domestic production of the bivalent HPV vaccine is handled by two companies, with an annual production capacity of 55 million doses, sufficient to meet market demand [6]. - All vaccines produced have received pre-certification from the World Health Organization, ensuring their quality and safety [6]. Group 4: Broader Health Impact - The inclusion of the HPV vaccine in the national immunization program marks a new phase in China's immunization efforts, contributing to global health equity [7]. - The initiative involves collaboration across multiple departments to ensure smooth implementation and effective monitoring of vaccination and associated risks [7].

Core Viewpoint - The inclusion of the HPV vaccine in the national immunization program is a significant step towards reducing cervical cancer incidence in China, but challenges remain in achieving effective vaccination rates and addressing existing immunity gaps among older populations [1][2]. Group 1: HPV Vaccine Implementation - The HPV vaccine will be provided for free to girls aged 13 and above, starting from November 10, 2025, as part of the national immunization program [1]. - The vaccination plan aims to ensure that girls receive two doses of the bivalent HPV vaccine, spaced six months apart, to establish immunity before potential sexual exposure [1][3]. - Previous initiatives in 18 provinces have shown that actual vaccination rates are not ideal, with school-based vaccination being a critical bottleneck [1][2]. Group 2: Target Population and Age Considerations - The decision to target girls aged 13 aligns with research indicating that vaccination between the ages of 9-14 generates a stronger immune response [3][4]. - There is a significant immunity gap among older populations who may not yet be eligible for cancer screenings, highlighting the need for ongoing vaccination efforts [2][10]. Group 3: Challenges in Implementation - The feasibility of mobilizing parents for vaccination in higher grades of elementary school is questioned, suggesting that early middle school is a more suitable time for vaccination [4][5]. - The notification includes provisions for catch-up vaccinations for girls who miss the initial opportunity, allowing for one additional dose before the age of 18 [8][10]. Group 4: Vaccine Market Dynamics - The government procurement price for the bivalent HPV vaccine is set at approximately 27.5 yuan per dose, with a total budget of about 425 million yuan for 2025 [14]. - The market for the HPV vaccine is expected to stabilize in terms of pricing, as the focus shifts from price competition to ensuring vaccine quality [15][17]. Group 5: Integration of Preventive Measures - The integration of HPV vaccination with cervical cancer screening is seen as a cost-effective strategy to reduce overall healthcare expenditures related to cervical cancer treatment [13]. - The potential for optimizing screening strategies in the "post-vaccine era" is highlighted, with suggestions for extending screening intervals as vaccination rates increase [13].

Core Viewpoint - The Chinese government has announced the inclusion of the HPV vaccine in the national immunization program, providing free vaccinations for girls born after November 10, 2011, starting from November 10, 2025 [1] Group 1 - The announcement was made by seven ministries, including the National Health Commission and the Ministry of Education [1] - The program will offer two doses of the bivalent HPV vaccine, with a six-month interval between doses [1] - The China Center for Disease Control and Prevention will be responsible for gathering vaccine demand information and conducting centralized procurement [1]